Universal method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in biological samples

Abstract

The present invention relates to a new method for capturing and analysing antibody-drug conjugates (ADCs) in biological samples, such as e.g., serum. Methods for analysing the structure of an antibody-drug conjugate (ADC) in a biological sample and methods for assessing the stability of an ADC are also provided.

Claims

1. A method for analysing the structure of an antibody-drug conjugate (ADC) present in a biological sample of a subject, wherein the ADC comprises an Fc domain of human origin, said method comprising the steps of: a) contacting said biological sample with a reagent binding specifically the Fc domain of the antibody moiety of the ADC wherein the reagent binds an Fc domain of human origin, but not an Fc domain from any other species; b) isolating the ADC molecules bound by said reagent; c) reducing the ADC isolated in step b) with a reducing agent that allows reduction of the disulfide bonds of the antibody moiety of the isolated ADC, thereby preventing ADC dissociation; and d) analysing the structure of the reduced ADC of step c).

2. The method of claim 1, wherein said subject is a subject previously administered with said ADC.

3. The method of claim 1, wherein said method comprises a preliminary step of adding said ADC to said biological sample.

4. The method of claim 1, wherein analysing the structure of the reduced ADC in step d) involves determining the drug-antibody ratio (DAR) of said reduced ADC.

5. The method of claim 1, wherein the structure of the reduced ADC is analysed in step d) by mass spectrometry.

6. The method of claim 1, wherein the ADC is a compound of formula (I):
Ab-(L-D).sub.n   (I) or a pharmaceutically acceptable salt thereof, wherein Ab is an antibody, or an antigen binding fragment thereof, capable of binding to the human IGF-1R which comprises the three heavy-chain CDRs of sequence SEQ ID No. 1, 2 and 3 and the three light-chain CDRs of sequence SEQ ID No. 4, 5 and 6; L is a linker; D is a drug moiety of the following formula (II): ##STR00016## wherein: R.sub.2 is COOH, COOCH.sub.3 or thiazolyl; R.sub.3 is H or (C.sub.1-C.sub.6)alkyl; R.sub.9 is H or (C.sub.1-C.sub.6)alkyl; m is an integer comprised between 1 and 8; the wavy line indicates the point of attachment to L; and n is 1 to 12.

Description

LEGEND OF THE FIGURES

(1) FIG. 1: Separation of ADC1 fragments obtained after immunoprecipitation from serum and reduction using a PLRP-S column and MS detection (A). Deconvoluted spectra of LC0, LC conjugated to 1 payload (LC1) (B) and HC0, HC conjugated to 1, 2 and 3 payloads (HC1, HC2 and HC3, respectively) (C)

(2) FIG. 2: In vitro evolution of ADC1 fragments in sera from mice (A), rat (B) and cynomolgus monkey (C). ADC1 was spiked in serum at 100 μg/mL and incubated at 37° C. for 11 days. Aliquots were taken at the indicated time points, ADC was immunoprecipitated, reduced and analysed by LC-MS. Comparison of the mean DAR evolution versus time in the 3 different sera (D). The experiment was done in triplicate Error bars indicate SD.

(3) FIG. 3: In vitro stability studies of ADC1 (A) and ADC2 (B) in cynomolgus monkey serum by LC-MS

(4) ADC1 and ADC2 were spiked in cynomolgus serum at 100 μg/mL and incubated at 37° C. for 11 days. Aliquots were taken at the indicated time points, ADCs were immunoprecipitated, reduced and analysed by LC-MS. Comparison of the average DAR evolution versus time for the two ADCs (C). The experiment was done in triplicate. n=6; Error bars indicate SD.

(5) FIG. 4: In vitro stability data of ADC1 and ADC2 in cynomolgus monkey serum by ELISA. ADC1 and ADC2 were spiked in cynomolgus serum at 100 μg/mL and incubated at 37° C. for 11 days. Graph representing the concentrations of total Ab and ADCs were plotted versus the incubation time in days for both ADC1 and ADC2 (A). Data were normalized in percentage of the total Ab concentration at each time point. The percentages total Ab (100%) and ADCs were plotted versus the incubation time in days. n=6 (B); Error bars indicate SE.

(6) FIG. 5: In vitro evolution of ADC1 fragments in sera from mice (A), rat (B) and cynomolgus monkey (C). ADC1 was injected at 5 mg/kg. Aliquots were taken at the indicated time points, ADC was immunoprecipitated, reduced and analysed by LC-MS. The experiment was done in triplicate. Error bars indicate SD.

(7) FIG. 6: Comparison of the DAR evolution in function of time in the 2 different Monkeys (Cyno 1 and Cyno 2). The experiment was done in triplicate. Error bars indicate SD.

(8) FIG. 7: Comparison of the mean DAR evolution in function of time in in vitro experiments (cynomolgus monkey serums, values of FIG. 3 C) and in vivo experiments (cynomolgus monkeys, values of FIG. 6). Error bars indicate SD.

EXAMPLES

(9) Materials and Methods

(10) Reagents and Materials

(11) To prepare ADC1 and ADC2 conjugated at native cysteines with an average of four drugs per antibody, humanized mAbs were partially reduced and conjugated to maleimide-vc-auristatins (cleavable and non-cleavable linkers, two different auristatins) as previously described[18].

(12) More particularly, ADC1 is an ADC targeting IGF-1R described in the examples of the application WO 2015/162291. ADC2 is Brentuximab vedotin (INN, trade name Adcetris), an ADC targeting CD30.

(13) Cynomolgus (Macaca fascicularis) and rat (Sprague Dawley) sera were obtained from Bioprim (Perpignan, France) and mouse serum from athymic nude (Charles River Laboratories). CaptureSelect™ Human IgG-Fc PK Biotin conjugate was purchased from Life Technologies (Saint Aubin, France) and Dynabeads M-280 Streptavidin from Invitrogen (Saint Aubin, France). Guanidin hydrochlorid, Ethylenediaminetetraacetic acid (EDTA), Hydroxide sodium (NaOH), Trizma Base (Tris), Trifluoroacetic acid (TFA) and Sodium dihydrogen phosphate were obtained from Sigma-Aldrich (Saint-Quentin-Fallavier, France), acetonitrile (ACN) from Merck (Fontenay-sous-Bois, France) and Dithiothreitol (DTT) from Agilent Technologies (Les Ulis, France). Sodium chloride and Sodium phosphate dibasic were purchased from VWR (Fontenay-sous-Bois, France), HEPES and HBS-EP buffers from GE Healthcare (Vélizy-Villacoublay, France) and PBS from Biochrom (Fontenay-sous-Bois, France). All the aqueous solutions were prepared using ultra-pure water.

(14) ADC Stability Study

(15) ADCs were spiked in sterile mouse, rat or cynomolgus serum at a concentration of 100 μg/ml. Aliquots of 100 μl were incubated at +37° C. in Protein LoBind Tube (Eppendorf, Montesson, France). At specific times (day 1, day 4, day 7 and day 11) samples were removed from the oven and stored at −20° C. until sample processing and analysis.

(16) ADC Samples Treatment for LC-MS Assay

(17) ADCs were immunoprecipitated from sera using the following protocol. Briefly, 100 μl M-280 Streptavidin magnetics beads suspension were washed three times with HBS-EP buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v Surfactant P20) and incubated for 30 min at RT with the CaptureSelect™ Human IgG-Fc PK Biotin conjugate. Serum samples from stability studies were then added to the beads and incubated for 2 h at RT. After washing steps with HBS-EP buffer and HBS buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA pH 7.6), the ADC was eluted with 0.4% TFA in water. After freeze drying, the samples were reconstituted and incubated with 34 mM DTT in denaturing buffer (6 M Guanidine, 0.1 M Tris, 2 mM EDTA pH 8.0) for 45 min at 56° C.

(18) Acetic acid was then added to quench the reaction and samples were analysed by LC-MS.

(19) LC-MS Analysis

(20) Reverse phase separation was performed on an ultra-high performance liquid chromatography (UHPLC) system (Acquity UPLC H-Class Bio system, Waters) coupled to a Synapt G2si mass spectrometer, instrument control was performed using MassLynx® software (Waters).

(21) The reduced samples were directly injected on a PLRP-S column (2.1×150 mm 8 μm, 1000 Å, Agilent) heated at 80° C. with a flow rate of 0.5 ml/min. Elution was performed with water as eluent A and acetonitrile as eluent B, both containing 0.05% TFA. The following elution gradient was applied, B was raised from 30% to 45% in 13 min and then from 45% to 95% in 2 min. The column was washed using 95% B and equilibrated using 30% B for 10 min. The autosampler temperature was set at 10° C. The mass spectrometer was operated in positive mode and data were recovered from m/z 500 to 3000 with voltages of 2.5 kV and 45 V for capillary and sample cone, respectively. The source and desolvation temperatures were set at 100° C. and 300° C., respectively.

(22) Data Processing

(23) Data were analysed using Biopharmalynx™ (Waters) software. Two representative time windows in the total ion chromatogram were selected to extract the corresponding mass spectrum of the LC fragments (LC, [LC+1 payload], [LC+1 payload+18 Da]) and HC fragments (HC, [HC+1 payload], [HC+1 payload+18 Da], [HC+2 payloads], [HC+2 payloads+18 Da], [HC+2 payloads+36 Da] and HC+3 payloads). Deconvolution was performed by MaxEnt™ to obtain the distribution profile of the different drug-loaded fragments. The MS peak area for each fragment was then used to calculate the average Drug to Antibody Ratio (DAR) using the following formula:

(24) $\mathrm{Average}\mathrm{DAR}=2\left[\underset{n=0}{\overset{1}{.Math.}}\left[{\mathrm{nA}}_{\mathrm{LCn}}\text{/}\underset{n=0}{\overset{1}{.Math.}}\left(A_{\mathrm{LCn}}\right)\right]+\underset{n=0}{\overset{3}{.Math.}}\left[{\mathrm{nA}}_{\mathrm{HCn}}\text{/}\underset{n=0}{\overset{3}{.Math.}}\left(A_{\mathrm{HCn}}\right)\right]\right],$
with A=peak area, n=loaded drug, LC=Light Chain and HC=Heavy Chain
Total Antibody and ADC ELISAs

(25) Four different Ligand Binding Assay (LBAs) systems were used to determine Total Ab or ADC concentrations for ADC1 and ADC2[19]. More precisely, an antigen-specific assay was used for ADC1 and a universal method for ADC2. For the ADC quantification, specific anti-drugs were used relevant to the payload of the ADC.

(26) Briefly, standard microtiter plates (MSD, Gaithersburg, USA) were coated at a concentration of 2 μg/ml Goat anti Human IgG, Monkey adsorbed antibody (SouthernBiotech) for Total Ab or of 3 μg/ml mouse monoclonal antibody raised against the payloads (Epitope Diagnostic Inc.) for ADC assays in PBS. After an overnight incubation at 4° C., plates were treated with blocking buffer (3% MSD Blocker A (MSD, Gaithersburg, USA)) for 1 h at 37° C. In parallel, the standard curves (1000 ng/ml-0.488 ng/ml) using reference immunoconjugates (ADC1 or ADC2) were prepared in assay buffer (1% MSD Blocker in TBS+0.02% Tween 20). Serum samples were diluted to 1:1000 or 1:5000 in a separate 2-ml deep 96-well polypropylene plate in MSD assay buffer. Standards and samples were then loaded onto the assay plate and incubated for 1 h at 37° C. After washing with 1×PBS, the detection step was done using a 2.5 μg/ml solution of the biotinylated antigen for the ADC1 (in house preparation) or a goat anti-human Ig Kappa sulfo-tag solution (in house preparation) diluted to 1 μg/ml in assay buffer for ADC2. After a 30-min incubation at 37° C., and a washing step, the detection was allowed by adding 150 μl of a 2×MSD-read T buffer containing surfactant (MSD, Gaithersburg, USA) just before reading using MSD Sector Imager.

(27) Results

(28) LC-MS Distribution Profile of ADC Fragments

(29) The LC-MS analysis of reduced ADC1 (FIG. 1A) resulted in six major peaks as identified by Lyon R P et al[11,20]. The deconvoluted mass spectra of the six peaks for ADC1 reported in FIGS. 1B (for LC) and 1C (for HC) showed masses of 23492.9 Da and 24551.3 Da that matched with LC0 (MTheo=23493.2 Da) and LC+1 payload (MTheo=24551.6 Da) and masses of 50763.4 Da, 51821.4 Da, 52879.7 Da and 53937.5 Da that matched with HC0 (MTheo=50763.3 Da), HC+1 payload (MTheo=51821.7 Da), HC+2 payloads (MTheo=52880.0 Da), HC+3 payloads (MTheo=53938.4 Da). We also measured for each loaded-fragment, peaks with an increment of mass of +18 Da (for LC1, HC1) and +32 Da for HC2, matching with maleimide hydrolysis as already described by Shen et al[21]. The same types of results were also obtained for ADC2 (data not shown).

(30) Stability of ADC1 in Sera from Mouse, Rat and Cynomolgus Monkey by LC-MS Analysis

(31) ADC1 was spiked in sera from mouse, rat and cynomolgus monkey at +37° C. The ADC was recovered by immunoprecipitation with the CaptureSelect™ Human IgG-Fc PK Biotin conjugate at different time points and analysed by LC-MS after reduction, to characterize the evolution of the different ADC fragments. In mouse serum (FIG. 2A), the LC and HC without payload (LC0 and HC0, respectively) increased from DO to D4 and then were stabilized. This was correlated with the hydrolysis of the maleimide function of the payload preventing its further deconjugation in serum as reported by several groups[22-25]. Conversely, the fragments LC1, HC2 and HC3 decreased from day 0 to day 4 and then were stabilized. The HC1 fragment remained globally at the same level because its own deconjugation was offset by the ones of HC2 and HC3. The same deconjugation profile for ADC1 was observed in the serum from rat (FIG. 2B) and from cynomolgus monkey (FIG. 2C).

(32) The average DAR evolution in serum from mice, from rat and cynomolgus is summarized in FIG. 2D. It decreased similarly in the three types of sera from DAR 4 at day 0 to DAR 2.5 at day 4 and then remained stable (around DAR 2) along the days 4 to 11. These data are in accordance with what is described in literature for a maleimide linker-based ADC, the mechanism of drug release from maleimide adducts likely involves a retro-michael reaction that takes place in serum as discussed above.

(33) Comparison of the Stability of Two ADCs In Vitro in Cynomolgus Monkey Serum by LC-MS and ELISA

(34) The ADC1 and ADC2 were spiked (at 100 μg/μL) in cynomolgus serum and incubated at 37° C. for 11 days. Samples were analysed at different time points using both LC-MS analysis for the average DAR evaluation after immunoprecipitation with the CaptureSelect™ Human IgG-Fc PK Biotin conjugate, and sandwich ELISA-based methods for quantification of total Abs and ADCs[26].

(35) The analyses of ADCs by LC-MS, at the indicated time points showed that fragments profiles for ADC1 (FIG. 3A) and ADC2 (FIG. 3B) were similar. The average DAR evolution decreased from DAR 4 and 4.5 at day 0, to DAR 2.5 and 2.0 at day 4 for ADC1 and ADC2, respectively and then was stable along the days 4 to 11 (FIG. 3C).

(36) The amount of total antibody and ADC, in serum samples was evaluated in parallel by a quantitative sandwich ELISA. The total antibody assay detects both naked and conjugated antibody, whereas the ADC assay detects only antibody linked at least to one payload.

(37) FIG. 4A clearly shows that in cynomolgus serum, the total Ab level (˜100 μg/ml) remained stable over the 11-day period, for both ADC1 and ADC2. In contrast, the ADC concentration decreased during this period for both ADC1 and ADC2. The normalization of the data against the total Ab concentration at each time point (FIG. 4B) emphasizes that the ADC level decreased mainly during the four first days for both ADC1 and ADC2. Thereafter the ADC concentration tended to remain stable over the 7 following days. These data are correlated with those obtained by the LC-MS analysis, confirming that deconjugation occurs mainly during an initial 4-day period. The diminution of the ADC level by ELISA reflects the appearance of DAR0, however, no information relative to the average DAR is available, in contrast to the LC-MS method.

CONCLUSION

(38) In this study, we present a new universal method to immunocapture and analyse by LC-MS the stability of ADCs in sera from preclinical species. Using a single protocol for samples preparation allows the stability study of ADCs in sera from mouse, rat and cynomolgus monkey. Furthermore, we demonstrated that this type of protocol can be applied to different ADCs, the results obtained in cynomolgus serum using immunoprecipitation with the CaptureSelect™ Human IgG-Fc PK Biotin conjugate and LC-MS analysis were validated using an ELISA orthogonal method. To summarize, as the ligand used for immunoprecipitation is targeting the Fc part of mAb, this protocol can be applied to compare and analyse the stability of virtually all ADCs and mAbs in sera for preclinical studies without the need to prepare specific tools. To our knowledge, this is the first time that this type of sample preparation coupled to LC-MS analysis is described to characterize DAR evolution for ADC in vitro stability studies. Finally, additional experiments show that this method can also be used to study the DAR evolution and the payload [11] localisation after the ADC administration in vivo.

(39) A particular embodiment of the invention consists of the implementation of a reduction step before the MS analysis.

(40) A particular embodiment of the invention consists of the use of HBS-EP/HBS as washing buffer.

(41) A particular embodiment of the invention consists of the use of magnetic beads as support for the capture of the agent anti human Fc (such as for example CaptureSelect™ Human IgG-Fc immobilization).

(42) Differentiation Elements Between mAb (ThermoFisher Protocol) and ADC (CIPF Protocol) Immunoprecipitation

(43) TABLE-US-00001 Thermo (mAb) CIPF (ADC) Support for CaptureSelect ™ MSIA Magnetic beads Human IgG-Fc immobilization Washing buffer PBS or Hepes HBS-EP/HBS Reduction before MS analysis None Yes : to simplify the number of molecules to be analysed
Washing Steps:

(44) The HBS-EP buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v

(45) Surfactant P20) was used instead of PBS because it contains a surfactant molecule which allows the elimination of plasma proteins non-specifically adsorbed on support.

(46) The further washing step with HBS alone was introduced to remove the surfactant P20, not compatible with mass analysis.

(47) Reduction Step:

(48) This step was introduced because elution of the ADC (the drugs are conjugated on the sulfhydryl groups of the inter-chain cysteine residues) induces the ADC dissociation. The generated fragments have different molecular weights comprised between 25 and 150 KDa with different mass response factors, which not allows the determination of the % of each species used to calculate the drug to antibody ratio (DAR).

(49) The introduction of the reduction step leads to only two populations of 25 and 50 KDa fragments used to calculate the DAR in order to follow the ADC de-conjugation in sera and to characterize precisely the cleavage and modification of the payloads.

(50) This reduction step would also allow a more precise determination of the DAR evolution for ADCs with drugs conjugated on the amine groups of the lysine residues in sera, because without reduction, the highly-conjugated species would be underestimated.

(51) In Vivo Stability of ADC1 in Cynomolgus Monkey (Male Macaca fascicularis) by LC-MS Analysis

(52) The ADC1 was administrated to two cynomolgus monkeys at doses of 5 mg/kg by intravenous route. Blood samples were collected before ADC injection and after 4, 24, 96, 168 and 336 hours following the injection. Samples sera were stored at −80° C.

(53) The ADC was recovered by immunoprecipitation (from both cynomolgus monkey sera) with the CaptureSelect™ Human IgG-Fc PK Biotin conjugate at different time points and analysed by LC-MS after reduction, to characterize the evolution of the different ADC fragments (FIGS. 5A and 5 B). The LC and HC without payload (LC0 and HC0, respectively) increased from 4 H to 336 H. Conversely, LC1 and HC2 fragments decreased, HC1 increased until 96 H and then decreased.

(54) The average DAR evolution is summarized in FIG. 6. It decreased similarly in both monkeys, from DAR 4 at day 0 to DAR 2.5 at day 7 and then remained stable (around DAR 2.5) from day 7 to day 14. These data are in accordance with what is described in literature for a maleimide linker-based ADC.

(55) In Vivo and In Vitro ADC Serum Stability Comparison

(56) As shown in FIG. 7, the in vivo ADC deconjugation profile in serum is similar to the one obtained in vitro. It decreased similarly from DAR 4 at day 0 to DAR 2.5 at day 7 and then remained stable from day 7 to day 14. No DAR evolution was observed between 7 and 14 days, which could be interpreted as the stabilisation effect of the succinimide ring opening described for similar linkers).

REFERENCES

(57) [1] Beck, A. and Reichert, J. M., Antibody-drug conjugates: present and future. MAbs., 6 (2014) 15. [2] Beck, A., Terral, G., Debaene, F., Wagner-Rousset, E., Marcoux, J., Janin-Bussat, M. C., Colas, O., Van Dorsselaer, A., and Cianferani, S., Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates. Expert. Rev. Proteomics., (2016) 1. [3] Beck, A., Haeuw, J. F., Wurch, T., Goetsch, L., Bailly, C., and Corvaia, N., The next generation of antibody-drug conjugates comes of age. Discov. Med., 10 (2010) 329. [4] Wiggins, B., Liu-Shin, L., Yamaguchi, H., and Ratnaswamy, G., Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates. J. Pharm. Sci., 104 (2015) 1362. [5] Chari, R. V., Miller, M. L., and Widdison, W. C., Antibody-drug conjugates: an emerging concept in cancer therapy. Angew. Chem. Int. Ed Engl., 53 (2014) 3796. [6] Klinguer-Hamour, C., Strop, P., Shah, D. K., Ducry, L., Xu, A., and Beck, A., World Antibody-Drug Conjugate Summit, Oct. 15-16, 2013, San Francisco, Calif. MAbs., 6 (2014) 18. [7] Valliere-Douglass, J. F., McFee, W. A., and Salas-Solano, O., Native intact mass determination of antibodies conjugated with monomethyl Auristatin E and F at interchain cysteine residues. Anal. Chem., 84 (2012) 2843. [8] Debaene, F., Boeuf, A., Wagner-Rousset, E., Colas, O., Ayoub, D., Corvaia, N., Van Dorsselaer, A., Beck, A., and Cianferani, S., Innovative native MS methodologies for antibody drug conjugate characterization: High resolution native MS and IM-MS for average DAR and DAR distribution assessment. Anal. Chem., 86 (2014) 10674. [9] Birdsall, R. E., McCarthy, S. M., Janin-Bussat, M. C., Perez, M., Haeuw, J. F., Chen, W., and Beck, A., A sensitive multidimensional method for the detection, characterization, and quantification of trace free drug species in antibody-drug conjugate samples using mass spectral detection. MAbs, (2015) 1. [10] Wakankar, A., Chen, Y., Gokarn, Y., and Jacobson, F. S., Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs., 3 (2011) 161. [11] Janin-Bussat, M. C., Dillenbourg, M., Corvaia, N., Beck, A., and Klinguer-Hamour, C., Characterization of antibody drug conjugate positional isomers at cysteine residues by peptide mapping LC-MS analysis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 981-982 (2015) 9. [12] Beck, A., Wagner-Rousset, E., Ayoub, D., Van Dorsselaer, A., and Sanglier-Cianferani, S., Characterization of therapeutic antibodies and related products. Anal. Chem., 85 (2013) 715. [13] Tibbitts, J., Canter, D., Graff, R., Smith, A., and Khawli, L. A., Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development. MAbs, (2015) 00. [14] Marcoux, J., Champion, T., Colas, O., Wagner-Rousset, E., Corvaia, N., Van Dorsselaer, A., Beck, A., and Cianferani, S., Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate. Protein Sci., 24 (2015) 1210. [15] Saber, H. and Leighton, J. K., An FDA oncology analysis of antibody-drug conjugates. Regul. Toxicol. Pharmacol., 71 (2015) 444. [16] Hengel, S. M., Sanderson, R., Valliere-Douglass, J., Nicholas, N., Leiske, C., and Alley, S. C., Measurement of in vivo drug load distribution of cysteine-linked antibody-drug conjugates using microscale liquid chromatography mass spectrometry. Anal. Chem., 86 (2014) 3420. [17] Sanderson, R. J., Nicholas, N. D., Baker Lee, C., Hengel, S. M., Lyon, R. P., Benjamin, D. R., and Alley, S. C., Antibody-conjugated drug assay for protease-cleavable antibodyGÇôdrug conjugates. Bioanalysis, 8 (2015) 55. [18] Wagner-Rousset, E., Janin-Bussat, M. C., Colas, O., Excoffier, M., Ayoub, D., Haeuw, J. F., Rilatt, I., Perez, M., Corvaia, N., and Beck, A., Antibody-drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion. MAbs., 6 (2014) 173. [19] Kaur, S., Xu, K., Saad, O. M., Dere, R. C., and Carrasco-Triguero, M., Bioanalytical assay strategies for the development of antibodyGÇôdrug conjugate biotherapeutics. Bioanalysis, 5 (2013) 201. [20] Lyon, R. P., Meyer, D. L., Setter, J. R., and Senter, P. D., Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues. Methods Enzymol., 502:123-38. doi: 10.1016/6978-0-12-416039-2.00006-9. (2012) 123. [21] Shen, B. Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K. L., Tien, J., Yu, S. F., Mai, E., Li, D., Tibbitts, J., Baudys, J., Saad, O. M., Scales, S. J., McDonald, P. J., Hass, P. E., Eigenbrot, C., Nguyen, T., Solis, W. A., Fuji, R. N., Flagella, K. M., Patel, D., Spencer, S. D., Khawli, L. A., Ebens, A., Wong, W. L., Vandlen, R., Kaur, S., Sliwkowski, M. X., Scheller, R. H., Polakis, P., and Junutula, J. R., Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat. Biotechnol., 30 (2012) 184. [22] Alley, S. C., Benjamin, D. R., Jeffrey, S. C., Okeley, N. M., Meyer, D. L., Sanderson, R. J., and Senter, P. D., Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug. Chem., 19 (2008) 759. [23] Lyon, R. P., Setter, J. R., Bovee, T. D., Doronina, S. O., Hunter, J. H., Anderson, M. E., Balasubramanian, C. L., Duniho, S. M., Leiske, C. I., Li, F., and Senter, P. D., Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates. Nat. Biotechnol., 32 (2014) 1059. [24] Tumey, L. N., Charati, M., He, T., Sousa, E., Ma, D., Han, X., Clark, T., Casavant, J., Loganzo, F., Barletta, F., Lucas, J., and Graziani, E. I., Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy. Bioconjug. Chem., 25 (2014) 1871. [25] Fontaine, S. D., Reid, R., Robinson, L., Ashley, G. W., and Santi, D. V., Long-term stabilization of maleimide-thiol conjugates. Bioconjug. Chem., 26 (2015) 145. [26] Xu, K., Liu, L., Dere, R., Mai, E., Erickson, R., Hendricks, A., Lin, K., Junutula, J. R., and Kaur, S., Characterization of the drug-to-antibody ratio distribution for antibodyGÇôdrug conjugates in plasma/serum. Bioanalysis, 5 (2013) 1057.